Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains

Onofrio Laselva, Steven Molinski, Valeria Casavola and Christine E. Bear
Molecular Pharmacology June 2018, 93 (6) 612-618; DOI: https://doi.org/10.1124/mol.118.111799
Onofrio Laselva
Programme in Molecular Medicine, Hospital for Sick Children, Toronto, Ontario, Canada (O.L., S.M., C.E.B.); Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy (V.C.); and Departments of Biochemistry and Physiology, University of Toronto, Toronto, Ontario, Canada (C.E.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Molinski
Programme in Molecular Medicine, Hospital for Sick Children, Toronto, Ontario, Canada (O.L., S.M., C.E.B.); Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy (V.C.); and Departments of Biochemistry and Physiology, University of Toronto, Toronto, Ontario, Canada (C.E.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valeria Casavola
Programme in Molecular Medicine, Hospital for Sick Children, Toronto, Ontario, Canada (O.L., S.M., C.E.B.); Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy (V.C.); and Departments of Biochemistry and Physiology, University of Toronto, Toronto, Ontario, Canada (C.E.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Bear
Programme in Molecular Medicine, Hospital for Sick Children, Toronto, Ontario, Canada (O.L., S.M., C.E.B.); Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy (V.C.); and Departments of Biochemistry and Physiology, University of Toronto, Toronto, Ontario, Canada (C.E.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Class I corrector VX-809 stabilizes the interaction between MSD1 and MSD2. (A, panel i) HEK293 cells were transiently transfected with MSD1 or MSD2-NBD2, or cotransfected with MSD1 and MSD2-NBD2 domains. (B, panel i) HEK293 cells were transiently transfected with MSD1 or MSD2, or cotransfected with MSD1 and MSD2 domains. Cells were treated for 24 hours at 37°C with DMSO, VX-809 (3 μM). The MSD1 fragment was detected with an antibody against the N-terminus of CFTR (i.e., mAb MM13-4), and the MSD2-NBD2 fragment was detected with an antibody against the C-terminus of CFTR (mAb 596) and MSD2 fragment with antibody A52. (A, panel ii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD1 normalized to calnexin loading. Data are representative of four biologic studies (**P < 0.01; ***P < 0.001). (A, panel iii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD2-NBD2 normalized to calnexin loading. Data are representative of four biologic studies (****P < 0.0001). (B, panel ii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD1 normalized to calnexin loading. Data are representative of four experiments (*P < 0.05; ***P < 0.001; ****P < 0.0001). (B, panel iii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD2 normalized to calnexin loading. Data are representative of four biologic studies (***P < 0.001). n.s., not significant.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    The class II corrector C4 stabilizes only MSD2-NBD2. (A, panel i) HEK293 cells were transiently transfected with MSD1 or MSD2-NBD2, or cotransfected with MSD1 and MSD2-NBD2 domains and treated for 24 hours at 37°C with DMSO or C4 (10 μM). The MSD1 fragment was detected with an antibody against the N-terminus of CFTR (i.e., mAb MM13-4), and the MSD2-NBD2 fragment was detected with an antibody against the C-terminus of CFTR (mAb 596). (A, panel ii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD1 normalized to calnexin loading. Data are representative of four biologic studies. (A, panel iii) Bar graphs show the mean (±S.E.M.) of the percentage of abundance of MSD2-NBD2 normalized to calnexin loading. Data are representative of three biologic studies (****P < 0.0001). n.s., not significant.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    C4 directly stabilizes MSD2 of CFTR. (A) Endoglycosidase sensitivity of the MSD2-CFTR fragment. Whole cell extracts of HEK293 cells transfected with A52-tagged MSD2-CFTR cDNA were treated with endoglycosidase H (H), peptide-N-glycosidase F (F), or untreated (–). (B) Effect of C4 (10 µM), TMA (500 nM), or VX-809 (3 µM) on the abundance of A52-tagged MSD2-CFTR in HEK293 cells. (C and D) MSD1 or MSD2 domains of CFTR were expressed in HEK293 cells in the presence or absence of C4 (10 μM) at 27°C. After 24 hours, protein synthesis was inhibited by addition of cycloheximide (0.5 mg/ml) with or without C4 (10 μM), and cells were collected after the indicated times for western blot analysis of whole cell extracts. (C, panel i; and D, panel i) The amount of CFTR protein at each time point was quantitated and expressed relative to that at time 0 and calnexin loading. Data are representative of three biologic studies (**P < 0.01).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Additive effect of VX-809 and C4 on correction of F508del-CFTR. (A–C) HEK293 cells were transiently transfected with F508del-CFTR, R170G/F508del, or F508del/R1070W-CFTR, and treated for 24 hours at 37°C with DMSO, VX-809 (3 μM) and/or C4 (10 μM). F508del-CFTR, R170G/F508del-CFTR, and F508del/R1070W-CFTR were detected with an antibody against the N-terminus of CFTR (MM13-4). (C) Mature, complex-glycosylated CFTR; (B) immature, core-glycosylated CFTR. (A, panel i; B, panel i; and C, panel i) Bars represent the mean (±S.E.M.) of the ratio C/(C+B) and are representative of three biologic studies (*P < 0.05; **P < 0.01; ***P < 0.001). (A, panel ii; B, panel ii; and C, panel ii) Bars represent the B+C and band B forms, normalized to DMSO and are representative of three biologic studies (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Stippled horizontal lines in (A and C) show prediction for additive effect of VX-809 plus C4 on C/C+B (left bar graph) or band C (right bar graph). Dotted horizontal line in (B) shows prediction for additive effect on band B (right bar graph). n.s., not significant.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Graphic hypothesis depicting putative interaction between VX-809 and C4 and key role of ICL1 (CL1) in corrector activity. (Upper panel) The illustration shows the MSD1 and F508del-NBD1 as peach colored and MSD2 and NBD2 as cyan colored. (Lower panel) The illustration on the left-hand side highlights the putative stabilizing effect of VX-809 (red) on MSD1 with its allosteric effect on MSD2. The illustration in the middle shows the putative stabilizing effect of C4 (green) on MSD2. The illustration on the right-hand side shows the putative interaction of VX-809 plus C4 on MSD2 (orange) and the primary role of CL1 on mediating correction by the combination.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -

      Supplemental Figure 1 - C4 stabilizes MSD2-NBD2 of CFTR

      Supplemental Figure 2 - Additive effect of VX-809 and C4 on processing of R170G-CFTR

      Supplemental Figure 3 - VX-809, C4 and glycerol correction of F508del-CFTR is additive with the R1070W second-site mutation

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 93 (6)
Molecular Pharmacology
Vol. 93, Issue 6
1 Jun 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Interacting Effect of Correctors in Combination

Onofrio Laselva, Steven Molinski, Valeria Casavola and Christine E. Bear
Molecular Pharmacology June 1, 2018, 93 (6) 612-618; DOI: https://doi.org/10.1124/mol.118.111799

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Interacting Effect of Correctors in Combination

Onofrio Laselva, Steven Molinski, Valeria Casavola and Christine E. Bear
Molecular Pharmacology June 1, 2018, 93 (6) 612-618; DOI: https://doi.org/10.1124/mol.118.111799
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics